ポスト
Just out in ESMO open @myESMO With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up https://t.co/R09Yg1XrPd
メニューを開く